Cadrenal Therapeutics, Inc. (CVKD)
↓ Download CSVKey ratios (FY2025)
-483.3%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2008 |
|---|---|---|---|---|---|
| Cost of Revenue | — | — | $220.1K | — | $220.1K |
| Operating Income | -$13.46M | -$10.96M | -$7.63M | — | — |
| Net Income | -$13.24M | -$10.65M | -$8.36M | — | — |
| EPS (Diluted) | $-6.64 | $-8.73 | $-9.29 | — | — |
| Total Assets | $4.33M | $10.12M | $8.52M | $778.2K | — |
| Total Liabilities | $1.59M | $2.68M | $826.9K | $6.33M | — |
| Shareholders' Equity | $2.74M | $7.44M | $7.69M | -$5.55M | — |
| Cash & Equivalents | $4.01M | $10.02M | $8.40M | $32.6K | — |
| Operating Cash Flow | -$12.60M | -$7.36M | -$3.53M | — | — |
| Capital Expenditures | $5.1K | $6.5K | $3.3K | — | — |
| Shares Outstanding | 2.34M | 1.78M | 868.2K | 8.19M | — |
| Dividends Per Share | $16.50 | $16.50 | — | — | — |